Brivudine: Difference between revisions

	WikiDoc Resources for Brivudine
Articles
Most recent articles on Brivudine Most cited articles on Brivudine Review articles on Brivudine Articles on Brivudine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Brivudine Images of Brivudine Photos of Brivudine Podcasts & MP3s on Brivudine Videos on Brivudine
Evidence Based Medicine
Cochrane Collaboration on Brivudine Bandolier on Brivudine TRIP on Brivudine
Clinical Trials
Ongoing Trials on Brivudine at Clinical Trials.gov Trial results on Brivudine Clinical Trials on Brivudine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Brivudine NICE Guidance on Brivudine NHS PRODIGY Guidance FDA on Brivudine CDC on Brivudine
Books
Books on Brivudine
News
Brivudine in the news Be alerted to news on Brivudine News trends on Brivudine
Commentary
Blogs on Brivudine
Definitions
Definitions of Brivudine
Patient Resources / Community
Patient resources on Brivudine Discussion groups on Brivudine Patient Handouts on Brivudine Directions to Hospitals Treating Brivudine Risk calculators and risk factors for Brivudine
Healthcare Provider Resources
Symptoms of Brivudine Causes & Risk Factors for Brivudine Diagnostic studies for Brivudine Treatment of Brivudine
Continuing Medical Education (CME)
CME Programs on Brivudine
International
Brivudine en Espanol Brivudine en Francais
Business
Brivudine in the Marketplace Patents on Brivudine
Experimental / Informatics
List of terms related to Brivudine

Brivudine
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	exclusion;
Routes of; administration	oral
ATC code	J05AB15 (WHO) ;
Pharmacokinetic data
Bioavailability	30%
Elimination half-life	16 hours
Excretion	mainly renal
Identifiers
	IUPAC name 5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione;
CAS Number	69304-47-8 ;
PubChem CID	446727;
ChemSpider	394011 ;
UNII	2M3055079H;
ChEMBL	ChEMBL31634 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C11H13BrN2O5
Molar mass	333.135 g/mol
3D model (JSmol)	Interactive image;
	SMILES Br[C@H]=CC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO;
	InChI InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1 ; Key:ODZBBRURCPAEIQ-PIXDULNESA-N ;
(what is this?) (verify)

← Older edit

VisualWikitext

Latest revision as of 20:42, 12 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Brivudine is an antiviral drug used in the treatment of herpes zoster.

History

Brivudine is a similar drug to acyclovir^{[clarification needed]}. The compound was first synthesized by scientists at the University of Birmingham in the UK in the 1970s. It was shown to be a potent inhibitor of the herpes simplex virus Type 1 (HSV-1) as well as the varicella zoster virus (VZV) by Erik De Clercq at the Rega Institute for Medical Research in Belgium in 1979. In the 1980s the drug became commercially available in East Germany, where it was marketed as Helpin by a pharmaceutical company called Berlin-Chemie.

Approvals

Brivudine is approved for use in Germany and other European countries including Italy.

Mechanism of Action

Brivudine is an analogue of the nucleoside thymidine. The drug works because it is able to be incorporated into the viral DNA, but then blocks the action of DNA polymerases, thus inhibiting viral replication. The active compound is the 5'-triphosphate of BVDU, which is formed in subsequent phosphorylations by viral thymidine kinase and presumably by nucleoside diphosphate kinase.

Research

A Cochrane Systematic Review examined the effectiveness of multiple antiviral drugs in the treatment of herpes simplex virus epithelial keratitis. Brivudine was found to be significantly more effective than idoxuridine in increasing the number of successfully healed eyes of participants.^[1]

The drug's name

Brivudine derives from the drug's chemical name of bromovinyldeoxyuridine or BVDU for short. The drug's full chemical description is (E)-5-(2-bromovinyl)-2-deoxyuridine. It is also sold as Bridic, Brivox, Brivudin, Helpin, Zerpex, Zonavir and Zostex.

Suppliers

Brivudine main supplier is Berlin-Chemie, now part of Italy's Menarini Group. The drug is approved for sale in Austria, Belgium, Germany, Greece, Italy, Luxembourg, Portugal and Spain. In Central America is provided Menarini Centro America and Wyeth.

References

↑ Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev. 12: CD002898. doi:10.1002/14651858.CD002898.pub4. PMID 21154352.

[Wilhelmus-1] Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev. 12: CD002898. doi:10.1002/14651858.CD002898.pub4. PMID 21154352.

[1]

@@ Line 4: / Line 4: @@
 | verifiedrevid = 459982797
 | IUPAC_name = 5-[(''E'')-2-bromoethenyl]-1-[(2''R'',4''S'',5''R'')-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
-| image = Brivudine - Brivudin.svg
+| image = Brivudine.png
 <!--Clinical data-->
@@ Line 44: / Line 44: @@
 | StdInChIKey = ODZBBRURCPAEIQ-PIXDULNESA-N
 }}
+              __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
 '''Brivudine''' is an [[antiviral drug]] used in the treatment of [[herpes zoster]].
@@ Line 65: / Line 71: @@
 ==References==
-{{reflist}}
+{{reflist|2}}
 {{Antivirals}}
 [[Category:Nucleosides]]
-[[Category:Pyrimidinediones]]
+[[Category:Drug]]
 [[Category:Organobromides]]
-[[Category:Anti-herpes virus drugs]]

v t e Antivirals, other than for HIV (primarily J05, also S01AD and D06BB)
Anti-herpesvirus (DNA, I)	guanine analogues (Aciclovir, Famciclovir, Ganciclovir, Penciclovir, Valaciclovir, Valganciclovir) • nucleoside analogues (Idoxuridine, Trifluridine, Vidarabine) • Cidofovir • Docosanol • Fomivirsen • Foscarnet • Tromantadine
HPV/MC (DNA, I)	Imiquimod • Podophyllotoxin
Hepatitis B (DNA, VII)	Adefovir • Interferon alfa-2b • Pegylated interferon alfa-2a • Entecavir • Lamivudine • Telbivudine • Tenofovir^†
Hepatitis C (RNA, IV)	Pegylated interferon alpha • Ribavirin • Taribavirin^† • Boceprevir^†
Picornavirus (RNA, IV)	Pleconaril^†
Anti-influenza agents (RNA, V)	Arbidol adamantane derivatives/M2 inhibitors (Amantadine, Rimantadine) neuraminidase inhibitors (Oseltamivir, Zanamivir, Peramivir^†)
HIV (Reverse, VI)	See HIV pharm
Other antiviral agents	general (Inosine, Interferon)
^†Undergoing clinical trials, not FDA approved.

Clinical data

AHFS/Drugs.com	International Drug Names
Pregnancy category	exclusion
Routes of administration	oral
ATC code	J05AB15 (WHO)
Pharmacokinetic data
Bioavailability	30%
Elimination half-life	16 hours
Excretion	mainly renal
Identifiers
IUPAC name 5-[(E)-2-bromoethenyl]-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
CAS Number	69304-47-8^N
PubChem CID	446727
ChemSpider	394011^Y
UNII	2M3055079H
ChEMBL	ChEMBL31634^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₁H₁₃BrN₂O₅
Molar mass	333.135 g/mol
3D model (JSmol)	Interactive image
SMILES Br[C@H]=CC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO
InChI InChI=1S/C11H13BrN2O5/c12-2-1-6-4-14(11(18)13-10(6)17)9-3-7(16)8(5-15)19-9/h1-2,4,7-9,15-16H,3,5H2,(H,13,17,18)/b2-1+/t7-,8+,9+/m0/s1^Y Key:ODZBBRURCPAEIQ-PIXDULNESA-N^Y
^NY (what is this?) (verify)